Abstract Purpose To assess toxicity and clinical outcome, in breast cancer patients treated with external beam partial breast irradiation (PBI) consisting of 35 Gy in 7 daily fractions (5 Gy/fraction). Materials and Methods Patients affected by early-stage breast cancer were enrolled in this phase II trial. Patients had to be 60 years old or over and treated with breast conservative surgery for early stage invasive carcinoma. Results Seventy-three patients were analyzed. Median follow-up was 40 months. The proposed schedule was well tolerated. No Grade 3 toxicity was documented. Late toxicity was assessable for all the treated patients. Two patients (2.7%) developed Grade 2 pain 6 months after PBI. Four patients (5%) developed asymptomatic ...
The aim of this study was to report 3-year outcomes of toxicity, cosmesis, and local control using a...
Context: Accelerated partial-breast irradiation (APBI) using various approaches is being increasingl...
Aims: Radiotherapy forms an integral part of breast-conserving treatment in early-stage breast cance...
Partial breast irradiation (PBI) is an effective adjuvant treatment after breast conservative surger...
Data de publicació electrònica: 18-11-2021Purpose: To present the first results of intraoperative ir...
Background and Purpose: Recent prospective studies have explored the partial breast irradiation (PBI...
The aim of this study is to assess the toxicity and cosmetic outcome of preoperative accelerated par...
BACKGROUND: We report the results of a single-institution, phase II trial of accelerated partial br...
PURPOSEThe results in terms of side effects vary among the published accelerated partial-breast irra...
The current standard therapeutic option for early stage breast cancer (EBC) employs a multimodality ...
Standard treatment of patients with early-stage breast cancer is breast-conserving surgery followed ...
Purpose: We sought to evaluate the feasibility and tolerability of a novel accelerated partial breas...
Purpose: To evaluate with a randomized clinical trial the possibility of treating the index quadrant...
AimsA pilot study was undertaken with the aim of documenting acute skin reactions and 2-year late ad...
Objectives:The aim of this study is to evaluate the feasibility and the related toxicity of hypofrac...
The aim of this study was to report 3-year outcomes of toxicity, cosmesis, and local control using a...
Context: Accelerated partial-breast irradiation (APBI) using various approaches is being increasingl...
Aims: Radiotherapy forms an integral part of breast-conserving treatment in early-stage breast cance...
Partial breast irradiation (PBI) is an effective adjuvant treatment after breast conservative surger...
Data de publicació electrònica: 18-11-2021Purpose: To present the first results of intraoperative ir...
Background and Purpose: Recent prospective studies have explored the partial breast irradiation (PBI...
The aim of this study is to assess the toxicity and cosmetic outcome of preoperative accelerated par...
BACKGROUND: We report the results of a single-institution, phase II trial of accelerated partial br...
PURPOSEThe results in terms of side effects vary among the published accelerated partial-breast irra...
The current standard therapeutic option for early stage breast cancer (EBC) employs a multimodality ...
Standard treatment of patients with early-stage breast cancer is breast-conserving surgery followed ...
Purpose: We sought to evaluate the feasibility and tolerability of a novel accelerated partial breas...
Purpose: To evaluate with a randomized clinical trial the possibility of treating the index quadrant...
AimsA pilot study was undertaken with the aim of documenting acute skin reactions and 2-year late ad...
Objectives:The aim of this study is to evaluate the feasibility and the related toxicity of hypofrac...
The aim of this study was to report 3-year outcomes of toxicity, cosmesis, and local control using a...
Context: Accelerated partial-breast irradiation (APBI) using various approaches is being increasingl...
Aims: Radiotherapy forms an integral part of breast-conserving treatment in early-stage breast cance...